CL2017000293A1 - Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014) - Google Patents

Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014)

Info

Publication number
CL2017000293A1
CL2017000293A1 CL2017000293A CL2017000293A CL2017000293A1 CL 2017000293 A1 CL2017000293 A1 CL 2017000293A1 CL 2017000293 A CL2017000293 A CL 2017000293A CL 2017000293 A CL2017000293 A CL 2017000293A CL 2017000293 A1 CL2017000293 A1 CL 2017000293A1
Authority
CL
Chile
Prior art keywords
divisional
hepatitis
compounds derived
treatment
pharmaceutical composition
Prior art date
Application number
CL2017000293A
Other languages
English (en)
Inventor
Pek Yoke Chong
John F Miller
Andrew James Peat
John Brad Shotwell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47746761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000293(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CL2017000293A1 publication Critical patent/CL2017000293A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>COMPUESTOS DERIVADOS DE BENZOFURANO; Y PROCESO PARA PREPARAR COMPUESTOS DERIVADOS DE BENZOFURANO (DIVISIONAL SOL. N° 393-2014)</p>
CL2017000293A 2011-08-19 2017-02-03 Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014) CL2017000293A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161525440P 2011-08-19 2011-08-19
US201261650681P 2012-05-23 2012-05-23

Publications (1)

Publication Number Publication Date
CL2017000293A1 true CL2017000293A1 (es) 2017-10-06

Family

ID=47746761

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2014000393A CL2014000393A1 (es) 2011-08-19 2014-02-17 Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion.
CL2017000293A CL2017000293A1 (es) 2011-08-19 2017-02-03 Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2014000393A CL2014000393A1 (es) 2011-08-19 2014-02-17 Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion.

Country Status (38)

Country Link
US (2) US8927593B2 (es)
EP (2) EP3199531A1 (es)
JP (2) JP6367712B2 (es)
KR (1) KR101913800B1 (es)
CN (1) CN103732065B (es)
AR (1) AR087563A1 (es)
AU (1) AU2012299295B2 (es)
BR (1) BR112014002845A2 (es)
CA (1) CA2844086A1 (es)
CL (2) CL2014000393A1 (es)
CO (1) CO6862153A2 (es)
CR (1) CR20140078A (es)
CY (1) CY1118399T1 (es)
DK (1) DK2744332T3 (es)
DO (1) DOP2014000034A (es)
EA (1) EA032841B1 (es)
ES (1) ES2611731T3 (es)
HR (1) HRP20161743T1 (es)
HU (1) HUE030300T2 (es)
IL (1) IL230487B (es)
IN (1) IN2014CN00572A (es)
JO (1) JO3281B1 (es)
LT (1) LT2744332T (es)
MA (1) MA35443B1 (es)
ME (1) ME02588B (es)
MX (1) MX354676B (es)
PE (1) PE20141201A1 (es)
PH (1) PH12014500385A1 (es)
PL (1) PL2744332T3 (es)
PT (1) PT2744332T (es)
RS (1) RS55462B1 (es)
SG (1) SG10201606883QA (es)
SI (1) SI2744332T1 (es)
SM (2) SMT201700028T1 (es)
TW (1) TWI538915B (es)
UY (1) UY34274A (es)
WO (1) WO2013028371A1 (es)
ZA (1) ZA201401020B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606646RA (en) * 2011-08-17 2016-09-29 Glaxosmithkline Llc Therapeutic methods
IN2014CN00572A (es) 2011-08-19 2015-04-03 Glaxo Group Ltd
EP3218485A1 (en) * 2014-11-10 2017-09-20 Glaxosmithkline Intellectual Property (No. 2) Limited Long acting pharmaceutical compositions for hepatitis c
SG11201703646SA (en) * 2014-11-10 2017-06-29 Glaxosmithkline Intellectual Property (No 2) Ltd Combination long acting compositions and methods for hepatitis c
KR20180006522A (ko) 2016-07-07 2018-01-18 삼성디스플레이 주식회사 액정 조성물 및 이를 포함하는 액정 표시 장치
WO2018026656A1 (en) * 2016-08-01 2018-02-08 University Of Pittsburgh -Of The Commonwealth System Of Higher Education Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles
AU2018227811A1 (en) * 2017-03-02 2019-09-19 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
IL276013B2 (en) * 2018-01-17 2024-03-01 Glaxosmithkline Ip Dev Ltd Pi4kiiibeta inhibitors
WO2021079984A1 (ja) * 2019-10-25 2021-04-29 大日本住友製薬株式会社 新規置換縮環型化合物
CN111026203B (zh) * 2019-12-02 2021-01-26 宁波德晶元科技有限公司 一种适用于真空热水壶的加热控制方法与系统
JP2023554665A (ja) * 2020-12-18 2023-12-28 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド ホウ素含有ピラゾール化合物、それらを含む組成物、それらの方法及び使用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
WO2001002601A2 (en) * 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
PT3078667T (pt) 2001-01-25 2018-12-28 The United States Of America Represented By The Sec Dep Of Health And Human Services Formulação de compostos de ácido borónico
UA79834C2 (en) * 2002-11-01 2007-07-25 Viropharma Inc Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
BRPI0619132A2 (pt) * 2005-12-01 2011-09-13 Wyeth Corp composto métodos para inibir a replicação de um vìrus de hepatite c, para tratar ou prevenir uma infecção viral de hepatite c em um mamìfero e para inibir rna polimerase dependente do rna de hepatite c, e, composição farmacêutica
NZ570257A (en) 2006-02-16 2011-11-25 Anacor Pharmaceuticals Inc Boron-containing small molecules as anti-inflammatory agents
CA2651212A1 (en) * 2006-05-02 2007-11-15 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
CA2963784A1 (en) * 2007-06-08 2008-12-18 Mannkind Corporation Ire-1.alpha. inhibitors
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
JP2011512341A (ja) 2008-02-14 2011-04-21 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス性複素環化合物
WO2009137500A1 (en) 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
TW201008933A (en) 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
EP2348863A4 (en) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
TW201138786A (en) 2010-02-19 2011-11-16 Glaxo Group Ltd Therapeutic compounds
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
AR080433A1 (es) 2010-03-02 2012-04-11 Merck Sharp & Dohme Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen.
WO2012067663A1 (en) 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
WO2012067664A1 (en) 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
SG10201606646RA (en) * 2011-08-17 2016-09-29 Glaxosmithkline Llc Therapeutic methods
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
IN2014CN00572A (es) 2011-08-19 2015-04-03 Glaxo Group Ltd

Also Published As

Publication number Publication date
UY34274A (es) 2013-04-05
SMT201700028T1 (it) 2017-03-08
BR112014002845A2 (pt) 2017-02-21
SMT201700028B (it) 2017-03-08
HUE030300T2 (en) 2017-04-28
EP2744332A4 (en) 2015-01-14
US20130237501A1 (en) 2013-09-12
DK2744332T3 (en) 2017-01-16
EP3199531A1 (en) 2017-08-02
PL2744332T3 (pl) 2017-03-31
JO3281B1 (ar) 2018-09-16
ZA201401020B (en) 2020-11-25
ES2611731T3 (es) 2017-05-10
CN103732065A (zh) 2014-04-16
TW201321390A (zh) 2013-06-01
IL230487B (en) 2019-06-30
US8927593B2 (en) 2015-01-06
LT2744332T (lt) 2017-01-10
HRP20161743T1 (hr) 2017-02-24
TWI538915B (zh) 2016-06-21
WO2013028371A1 (en) 2013-02-28
PE20141201A1 (es) 2014-10-03
AU2012299295A1 (en) 2014-02-20
KR20140054287A (ko) 2014-05-08
US9682999B2 (en) 2017-06-20
JP2017125010A (ja) 2017-07-20
MX2014001989A (es) 2014-02-27
CL2014000393A1 (es) 2014-08-01
CA2844086A1 (en) 2013-02-28
EA201490213A1 (ru) 2014-07-30
MX354676B (es) 2018-03-15
IN2014CN00572A (es) 2015-04-03
AU2012299295B2 (en) 2016-03-31
CO6862153A2 (es) 2014-02-10
SG10201606883QA (en) 2016-10-28
EA032841B1 (ru) 2019-07-31
KR101913800B1 (ko) 2018-11-01
IL230487A0 (en) 2014-03-31
DOP2014000034A (es) 2014-06-01
JP2014527529A (ja) 2014-10-16
CY1118399T1 (el) 2017-06-28
MA35443B1 (fr) 2014-09-01
EP2744332B1 (en) 2016-10-26
PT2744332T (pt) 2017-01-24
US20150080343A1 (en) 2015-03-19
PH12014500385A1 (en) 2020-06-22
ME02588B (me) 2017-06-20
RS55462B1 (sr) 2017-04-28
CR20140078A (es) 2014-03-20
CN103732065B (zh) 2016-10-26
EP2744332A1 (en) 2014-06-25
JP6367712B2 (ja) 2018-08-01
AR087563A1 (es) 2014-04-03
SI2744332T1 (sl) 2017-01-31

Similar Documents

Publication Publication Date Title
ECSP14004812A (es) Triazolopiridinas sustituidas
MX373711B (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b.
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
CO6811860A2 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
MX386981B (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7).
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
CL2016000381A1 (es) Compuestos antivirales
CO7111284A2 (es) Nucleósidos de espirooxetano de uracilo
CR20140405A (es) Apoptosis señal reguladores del inhibidor de quinasa
MX2020011810A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b.
CR20150629A (es) Compuestos químicos
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
ECSP13013011A (es) Triazolopiridinas
CR20130671A (es) Antagonistas de trpv4
CR20180069A (es) Derivados de la sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b
CO6650348A2 (es) Triazolopiridinas sustituidas
CR20130054A (es) Procesos para preparar compuestos antivirales
CL2013003056A1 (es) Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas.
AR095353A1 (es) Compuesto
CR20150160A (es) Derivados de macrólidos, su preparación y su uso terapéutico
DOP2016000232A (es) Compuestos químicos
AR102569A1 (es) Síntesis de inhibidor de pi3k, formas cristalinas y sales del mismo y una composición farmacéutica que lo comprende
AR086606A1 (es) Compuestos del complejo de fe(iii) para el tratamiento y profilaxis de los sintomas de la deficiencia de hierro y las anemias por deficiencia de hierro
AR101389A1 (es) Composición que contiene apomorfina y un catión de metal divalente